Skip to content

CERo Therapeutics (CERO) via Phoenix Biotech (PBAX) deck

CERo is an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Its lead product candidate is expected to enter clinical trials in 2024.

This post is for subscribers only


Already have an account? Sign In